Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody

Patricia A. Leonard, Kenneth J. Woodside, Kristene Gugliuzza, Sanjiv Sur, John A. Daller

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. Basiliximab and daclizumab are potent and relatively safe immunosuppressive induction agents used in transplantation. These chimeric or humanized monoclonal antibodies, respectively, act by binding to the a chain of interleukin-2 receptors on activated T lymphocytes. Herein, the authors describe successful transplant induction therapy with a humanized murine antibody in a patient with a history of anaphylaxis to a chimeric murine antibody. Methods. The authors report a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipated renal transplant that was canceled. Two weeks later, she received a second dose of basiliximab. Within 10 min of receiving the second dose, she developed chest tightness, shortness of breath, tongue swelling, diffuse pruritic rash, and skin flushing. Results. The authors hypothesized that her anaphylaxis was mediated by immunoglobulin (Ig) E antibodies to basiliximab. Consistent with this hypothesis, intradermal administration of a 1: 100 dilution of basiliximab induced a 10 × 10-mm flare. The authors sought to find an alternative immunosuppressive agent for this patient. The patient elicited prick and intradermal skin testing responses to horse and rabbit polyclonal antithymocyte antibody preparations. However, she mounted neither a prick nor an intradermal response to daclizumab. The patient was administered daclizumab without any adverse effects. Conclusions. The negative skin test and safe administration of daclizumab is surprising because the similarity of these hybrid antibodies would have predicted similar IgE responsiveness and clinical outcome. The authors propose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the presence of a negative skin test to the humanized agent.

Original languageEnglish (US)
Pages (from-to)1697-1700
Number of pages4
JournalTransplantation
Volume74
Issue number12
StatePublished - Dec 27 2002

Fingerprint

Antibodies, Monoclonal, Humanized
Anaphylaxis
Antibodies
Immunosuppressive Agents
Skin Tests
Immunoglobulin E
Transplants
Interleukin-2 Receptors
Exanthema
Tongue
Dyspnea
Horses
basiliximab
Thorax
Transplantation
daclizumab
Rabbits
T-Lymphocytes
Kidney
Skin

ASJC Scopus subject areas

  • Transplantation

Cite this

Leonard, P. A., Woodside, K. J., Gugliuzza, K., Sur, S., & Daller, J. A. (2002). Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation, 74(12), 1697-1700.

Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. / Leonard, Patricia A.; Woodside, Kenneth J.; Gugliuzza, Kristene; Sur, Sanjiv; Daller, John A.

In: Transplantation, Vol. 74, No. 12, 27.12.2002, p. 1697-1700.

Research output: Contribution to journalArticle

Leonard, PA, Woodside, KJ, Gugliuzza, K, Sur, S & Daller, JA 2002, 'Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody', Transplantation, vol. 74, no. 12, pp. 1697-1700.
Leonard, Patricia A. ; Woodside, Kenneth J. ; Gugliuzza, Kristene ; Sur, Sanjiv ; Daller, John A. / Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. In: Transplantation. 2002 ; Vol. 74, No. 12. pp. 1697-1700.
@article{d868dd234f7640caa3ca229ff20d8fb4,
title = "Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody",
abstract = "Background. Basiliximab and daclizumab are potent and relatively safe immunosuppressive induction agents used in transplantation. These chimeric or humanized monoclonal antibodies, respectively, act by binding to the a chain of interleukin-2 receptors on activated T lymphocytes. Herein, the authors describe successful transplant induction therapy with a humanized murine antibody in a patient with a history of anaphylaxis to a chimeric murine antibody. Methods. The authors report a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipated renal transplant that was canceled. Two weeks later, she received a second dose of basiliximab. Within 10 min of receiving the second dose, she developed chest tightness, shortness of breath, tongue swelling, diffuse pruritic rash, and skin flushing. Results. The authors hypothesized that her anaphylaxis was mediated by immunoglobulin (Ig) E antibodies to basiliximab. Consistent with this hypothesis, intradermal administration of a 1: 100 dilution of basiliximab induced a 10 × 10-mm flare. The authors sought to find an alternative immunosuppressive agent for this patient. The patient elicited prick and intradermal skin testing responses to horse and rabbit polyclonal antithymocyte antibody preparations. However, she mounted neither a prick nor an intradermal response to daclizumab. The patient was administered daclizumab without any adverse effects. Conclusions. The negative skin test and safe administration of daclizumab is surprising because the similarity of these hybrid antibodies would have predicted similar IgE responsiveness and clinical outcome. The authors propose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the presence of a negative skin test to the humanized agent.",
author = "Leonard, {Patricia A.} and Woodside, {Kenneth J.} and Kristene Gugliuzza and Sanjiv Sur and Daller, {John A.}",
year = "2002",
month = "12",
day = "27",
language = "English (US)",
volume = "74",
pages = "1697--1700",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody

AU - Leonard, Patricia A.

AU - Woodside, Kenneth J.

AU - Gugliuzza, Kristene

AU - Sur, Sanjiv

AU - Daller, John A.

PY - 2002/12/27

Y1 - 2002/12/27

N2 - Background. Basiliximab and daclizumab are potent and relatively safe immunosuppressive induction agents used in transplantation. These chimeric or humanized monoclonal antibodies, respectively, act by binding to the a chain of interleukin-2 receptors on activated T lymphocytes. Herein, the authors describe successful transplant induction therapy with a humanized murine antibody in a patient with a history of anaphylaxis to a chimeric murine antibody. Methods. The authors report a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipated renal transplant that was canceled. Two weeks later, she received a second dose of basiliximab. Within 10 min of receiving the second dose, she developed chest tightness, shortness of breath, tongue swelling, diffuse pruritic rash, and skin flushing. Results. The authors hypothesized that her anaphylaxis was mediated by immunoglobulin (Ig) E antibodies to basiliximab. Consistent with this hypothesis, intradermal administration of a 1: 100 dilution of basiliximab induced a 10 × 10-mm flare. The authors sought to find an alternative immunosuppressive agent for this patient. The patient elicited prick and intradermal skin testing responses to horse and rabbit polyclonal antithymocyte antibody preparations. However, she mounted neither a prick nor an intradermal response to daclizumab. The patient was administered daclizumab without any adverse effects. Conclusions. The negative skin test and safe administration of daclizumab is surprising because the similarity of these hybrid antibodies would have predicted similar IgE responsiveness and clinical outcome. The authors propose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the presence of a negative skin test to the humanized agent.

AB - Background. Basiliximab and daclizumab are potent and relatively safe immunosuppressive induction agents used in transplantation. These chimeric or humanized monoclonal antibodies, respectively, act by binding to the a chain of interleukin-2 receptors on activated T lymphocytes. Herein, the authors describe successful transplant induction therapy with a humanized murine antibody in a patient with a history of anaphylaxis to a chimeric murine antibody. Methods. The authors report a 42-year-old woman who received a dose of basiliximab without adverse reaction before an anticipated renal transplant that was canceled. Two weeks later, she received a second dose of basiliximab. Within 10 min of receiving the second dose, she developed chest tightness, shortness of breath, tongue swelling, diffuse pruritic rash, and skin flushing. Results. The authors hypothesized that her anaphylaxis was mediated by immunoglobulin (Ig) E antibodies to basiliximab. Consistent with this hypothesis, intradermal administration of a 1: 100 dilution of basiliximab induced a 10 × 10-mm flare. The authors sought to find an alternative immunosuppressive agent for this patient. The patient elicited prick and intradermal skin testing responses to horse and rabbit polyclonal antithymocyte antibody preparations. However, she mounted neither a prick nor an intradermal response to daclizumab. The patient was administered daclizumab without any adverse effects. Conclusions. The negative skin test and safe administration of daclizumab is surprising because the similarity of these hybrid antibodies would have predicted similar IgE responsiveness and clinical outcome. The authors propose that patients who develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the presence of a negative skin test to the humanized agent.

UR - http://www.scopus.com/inward/record.url?scp=0037184878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037184878&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 1697

EP - 1700

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -